medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2019, Number 2

<< Back Next >>

Acta Med 2019; 17 (2)

Breast cancer: experience of 11 years in the Hospital Ángeles Mocel

Chávez GA, González VC, Bieletto TO

Language: Spanish
References: 17
Page: 115-118
PDF size: 137.09 Kb.


ABSTRACT

Introduction: Breast cancer still is a public health problem worldwide. It is estimated that 2.1 million women are diagnosed each year, of which 626,680 die with a five-year survival rate of 30-50% in developed countries. Objective: Present a detailed panorama of the histopathological aspects of breast cancer in a group of Mexican women at the Angeles Mocel Hospital. Material and methods: Descriptive, observational, retrospective and cross-sectional study in 549 Mexican women diagnosed with breast cancer corroborated by histopathology of the Angeles Mocel Hospital during the 2006-2016 period. Results: We recorded an increase in the frequency of new cases in 2013, being 13.2% (73 cases) with a laterality of 51% in the right breast (280 cases). Average age of presentation: 55.1 years, with the most affected group being 41-50. The frequency of infiltrating ductal carcinoma was 67.4% (379 cases), demonstrating that the moderately differentiated or grade II histological grade is the most common within invasive ductal carcinomas occurring in 41.6% (158 cases). Conclusions: It was identified that, on average, 50 new cases of breast cancer are diagnosed each year, 2013 being the year with the highest number of registered cases. The age of presentation in Mexican women is still lower compared to developed countries, with the most common histological type being infiltrating ductal carcinoma.


REFERENCES

  1. Breast Cancer research [Internet]. Global Cancer Observatory. 2018 [Consultado 10 septiembre de 2018]. Disponible en: http://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf.

  2. Palacio LS, Lazcano E, Allen B, Hernández M. Diferencias regionales en la mortalidad por cáncer de mama y cérvix en México entre 1979 y 2006. Salud Publica Mex. 2009; 51 (2): 208-219.

  3. Estadísticas a propósito del día mundial de la lucha contra el cáncer de mama [Internet]. Instituto Nacional de Estadística y Geografía. 2015 [Consultado 5 de abril de 2018] Disponible en: http://www.inegi.org.mx/saladeprensa/aproposito/2015/mama0.pdf.

  4. Thun M, Linet MS, Cerhan JR, Haiman CA, Schottenfeld D. Cancer epidemiology and prevention. 3rd (eds.), New York, EUA: Oxford Press, 2006. pp. 107-141.

  5. Curbow B, Bowie J, Garza MA, McDonell K, Scott LB, Coyne CA et al. Community based cancer screening programs in older populations: making progress but can we do better. J Prev Med. 2004; 38 (6): 676-693.

  6. Miller AB. Conundrums in screening for cancer. Mini review. Int J Cancer. 2010; 126 (5): 1039-1046. doi: https://doi.org/10.1002/ijc.25081.

  7. Bray F, Piñeiros M. Cancer patterns: trends and projections in Latin America and the Caribbean: a global context. Salud Publica Mex. 2016; 58 (2): 104-117.

  8. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risk of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet. 1994; 343 (8899): 692-695.

  9. Guzmán K, Morales KV, Hernández AW, Gómez E, García F, Sánchez S. Carcinoma ductal infiltrante, el tipo de cáncer más común. iMedPub Jorunals. 2012; 8 (1): 1-8.

  10. Cárdenas J, Bargalló JE, Bautista V, Cervantes G, Erazo AA, Flores CH y cols. Consenso Mexicano sobre diagnóstico y tratamiento del cáncer mamario. 7ª ed. Ciudad de México: Elsevier, 2017. pp. 7-17.

  11. Norma Oficial Mexicana para la prevención, diagnóstico, tratamiento y vigilancia epidemiológica del cáncer de mama. [Internet]. Secretaría de Salud de México. 2003 [Consultado el 6 de junio de 2018]. Disponible en: http://www.salud.gob.mx/unidades/cdi/nom/041ssa202.html.

  12. Hernández AC, Romo AC, Clemenceau JR, Valenzuela TJ, Ayala PB. Hallazgos inmunohistoquímicos en una muestra de pacientes con cáncer de mama atendidos del 2009 al 2013 en el Hospital Ángeles Pedregal. Acta Med. 2017; 15 (3): 189-193.

  13. Schwartz AM, Henson DE, Chen D, Rajamarthandan S. Histologic grade remains a prognostic factor for breast cancer regardless of the number of positive lymph nodes and tumor size: a study of 161 708 cases of breast cancer from the SEER Program. Arch Pathol Lab Med. 2014; 138 (8): 1048-1052.

  14. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19 (5): 403-410.

  15. Rodríguez-Cuevas S, Macías CG, Franceschi D, Labastida S. Breast carcinoma presents a decade earlier in Mexican women than in women in the United States or European countries. Cancer. 2001; 91 (4): 863-868.

  16. Maffuz A, Rodríguez S, Labastida S, Espejo A. Características clinicopatológicas del cáncer de mama en una población de mujeres en México. Cirugía y Cirujanos. 2017; 85 (3): 201-207.

  17. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer: A study of 1,409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957; 11: 359-377.




2020     |     www.medigraphic.com